| Peter Hakim, | |
|
759 Chestnut St, Springfield, MA 01199-1001 | |
| (413) 794-0000 | |
| Not Available |
| Full Name | Peter Hakim |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 759 Chestnut St, Springfield, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144510066 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | DO166795 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Salem Hospital | Salem, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Salem Emergency Physicians Service, Pc | 8628061124 | 18 |
News Archive
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
Large-scale undertakings such as the Human Genome Project have produced massive amounts of data.
New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment.
Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).
› Verified 3 days ago
| Entity Name | Salem Health West Valley |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245237486 PECOS PAC ID: 7810804630 Enrollment ID: O20040225000830 |
News Archive
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
Large-scale undertakings such as the Human Genome Project have produced massive amounts of data.
New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment.
Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).
› Verified 3 days ago
| Entity Name | Salem Emergency Physicians Service, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063454395 PECOS PAC ID: 8628061124 Enrollment ID: O20040408000014 |
News Archive
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
Large-scale undertakings such as the Human Genome Project have produced massive amounts of data.
New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment.
Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Hakim, 1 Carriage City Plz, 1516, Rahway, NJ 07065-5181 Ph: (586) 491-6564 | Peter Hakim, 759 Chestnut St, Springfield, MA 01199-1001 Ph: (413) 794-0000 |
News Archive
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
Large-scale undertakings such as the Human Genome Project have produced massive amounts of data.
New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment.
Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).
› Verified 3 days ago
Agnieszka Nicora, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Main St Ste A, Springfield, MA 01107 Phone: 413-794-9560 Fax: 413-794-5884 | |
Bryanne E Macdonald, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 759 Chestnut St, Springfield, MA 01107 Phone: 413-794-3233 Fax: 413-794-9060 | |
Laura A Dove, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3300 Main St, Springfield, MA 01199 Phone: 413-794-7284 Fax: 413-794-7130 | |
Geoffrey William Fisher, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 759 Chestnut St Ste 2570, Springfield, MA 01199 Phone: 413-794-4373 | |
Lucienne Lutfy-clayton, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 759 Chestnut St, Springfield, MA 01199 Phone: 413-794-3233 | |
John P Santoro, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 759 Chestnut St, Springfield, MA 01199 Phone: 413-794-3233 | |
Matthew P Hinderaker, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 759 Chestnut St, Springfield, MA 01199 Phone: 413-794-3233 Fax: 413-794-9060 |